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Pemote Ischemic Preconditioning
rovides Early and Late Protection Against
ndothelial Ischemia-Reperfusion Injury in Humans
ole of the Autonomic Nervous System
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ondon, United Kingdom
OBJECTIVES The aim of this study was to characterize the time course and neuronal mechanism of remote
ischemic preconditioning (RIPC) of the vasculature in humans.
BACKGROUND Non-lethal ischemia of internal organs induces local (ischemic preconditioning) and systemic
(RIPC) resistance to lethal ischemia-reperfusion (IR) injury. Experimental RIPC has two
temporal components, is neuronally mediated, is induced by limb ischemia, and reduces
infarct size. In humans, RIPC prevents IR-induced vascular injury. Determining the time
course and mechanism is a prelude to clinical outcome studies of RIPC.
METHODS Endothelial IR injury was induced by arm ischemia (20 min) and reperfusion, and measured
by flow-mediated dilation. To establish if there are early and late phases, RIPC (three 5-min
cycles of ischemia of the contralateral arm) was applied immediately, 4, 24, and 48 h before
IR. To determine neuronal involvement, trimetaphan (autonomic ganglion blocker; 1 to 6
mg/min intravenous) was infused during the application of the RIPC stimulus.
RESULTS Flow-mediated dilation was reduced by IR (8.7  1.1% before IR, 4.9  1.2% after IR; p 
0.001), but not when preceded by RIPC (8.0 0.8% after IR; pNS); RIPC did not protect
after 4 h (4.9  1.1% after IR; p  0.001), but protected at 24 (8.7  1.1% after IR; p 
NS) and 48 h (8.8  1.4% after IR; p  NS). Trimetaphan attenuated early (8.3  1.1%
before IR, 4.2  0.9% after IR; p  0.05) and delayed (7.3  1.0% before IR, 2.3  0.6%
after IR, p  0.001) RIPC.
CONCLUSIONS Remote ischemic preconditioning in humans has two phases of protection against endothelial
IR injury; an early (short) and late (prolonged) phase, both of which are neuronally mediated.
The potential for late phase RIPC to provide prolonged protection during clinical IR
syndromes merits investigation. (J Am Coll Cardiol 2005;46:450–6) © 2005 by the





















fschemic preconditioning (IPC) is an innate mechanism
hat protects tissues from injury during ischemia and sub-
equent reperfusion (ischemia-reperfusion [IR] injury) (1).
reconditioning is initiated by brief, nonlethal periods of
schemia, and provides local tissue protection from the
ffects of further prolonged episodes of ischemia. In the
eart, IPC reduces experimental infarct size by up to 75% in
any different species (2–6). The effects of IPC are imme-
iate, triggered by release of several mediators (including
denosine and bradykinin) (7,8), and dependent on the
ctivation of complex second messenger systems (1). Imme-
iate protection lasts just a few hours, but is followed 24 h
ater by a “second window” of protection (9), lasting for 48
o 72 h (10) and dependent on the induction of protective
roteins (11). Although the magnitude of organ protection
n experimental models of IPC is substantial, this approach
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005, accepted April 13, 2005.as not yet led to clinical exploitation of preconditioning.
his is, in part, because of the logistical difficulties of using
schemia to precondition vital organs, either in advance of
linical IR injury that is predictable (such as primary
ngioplasty, coronary artery bypass surgery, or transplanta-
ion), or to maintain a persistent state of preconditioning in
eadiness for spontaneous cardiovascular events in high-risk
atients. Although much is known about the cellular mech-
nisms of both phases of IPC, remaining mechanistic
ncertainties have so far precluded a successful pharmaco-
ogic approach to preconditioning in humans (1).
It is now clear that IPC has systemic effects that result in
rotection from IR injury of tissues remote from those
ndergoing preconditioning (12). This aspect of pre-
onditioning, termed remote ischemic preconditioning
RIPC), was first described in the heart, where IPC initiated
n the vascular distribution of one coronary artery caused
rotection throughout the myocardium (13). It is now
pparent that protection from IPC spreads from distant
rgans to the heart (14,15) possibly via activation of the
utonomic nervous system (14,16–18), and/or humoral
actors (19,20). Mechanistically, RIPC resembles IPC and
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August 2, 2005:450–6 Remote Ischemic Preconditioning in Humansers (14,22,23) and in some studies provides protection for
p to 24 h (24).
We have recently demonstrated, in an in vivo model of
yocardial infarction, that short periods of limb ischemia
nduce RIPC and reduce experimental infarct size by 50%
25). In addition, using a human model of IR, we demon-
trated that IPC of one arm protects the contralateral arm
rom endothelial IR injury, consistent with a remote pre-
onditioning effect (25). These studies establish the princi-
le of using limb ischemia to induce RIPC, and indicate a
ay in which this technique might be investigated in the
linical setting. The aim of the present study was to
haracterize in humans the time course of protection from
IPC and, in particular, to establish if there are two
eparate phases of protection. In addition, we investigated
he mechanism of spread of protection to remote tissues.
efining these fundamental characteristics of human RIPC
s a prerequisite for the optimal design of future clinical
tudies.
ETHODS
ubjects. A total of 115 studies were performed on 16
ealthy volunteers (12 men, 4 women; mean age  SD
8.9  7.7 years; range 21 to 48 years) who gave informed
onsent. Studies were approved by the local research ethics
ommittee and performed in a temperature-controlled lab-
ratory (24°C to 26°C). All studies repeated in the same
olunteers were at least seven days apart.
nduction of IR. The nondominant forearm was made
schemic by inflating a 9-cm-wide blood pressure cuff placed
round the upper arm to a pressure of 200 mm Hg for 20
in, as described previously (26).
nduction of RIPC. Remote IPC was induced by inflating
9-cm-wide blood pressure cuff placed around the upper
art of the contralateral arm. The cuff was inflated to 200
m Hg for 5 min (ischemia), followed by a 5-min deflation.
he inflation/deflation cycle was performed three times.
ssessment of conduit vessel function. Endothelial func-
ion of the brachial artery was assessed by flow-mediated
ilation (FMD) of the brachial artery in the nondominant
rm, as previously described (27). A B-mode scan of the
rachial artery was obtained in longitudinal section between
and 10 cm above the antecubital fossa using a 7.0-MHz
inear array transducer (spatial resolution of 0.1 mm [28])
nd a standard Acuson XP10 system (Acuson, Mountain
iew, California). Longitudinal, electrocardiogram-gated,
Abbreviations and Acronyms
FMD  flow-mediated dilation
GTN  glyceryl trinitrate
IPC  ischemic preconditioning
IR  ischemia-reperfusion
RIPC  remote ischemic preconditioningnd-diastolic images were acquired every 3 s for offline
t
2nalysis. Arterial diameter over a 1- to 2-cm segment was
etermined for each image with the use of automatic
dge-detection software (Brachial Tools, Iowa City, Iowa).
lood flow was manipulated in the brachial artery by a
-cm-wide blood pressure cuff placed around the forearm
mmediately below the antecubital fossa. After 1 min of
aseline flow, the cuff was inflated to 300 mm Hg for 5 min
nd released, resulting in a brief episode of reactive
yperemia. Brachial artery diameter changes in response to
lood flow were assessed for a further 5 min. Blood flow
elocity was continuously monitored by pulsed-wave Dopp-
er. The dilator response of the brachial artery to glyceryl
rinitrate (GTN) (25 g sublingually) was used to assess
ndothelium-independent dilation.
xperimental protocols. EFFECT OF IR ON VASCULAR
ILATOR FUNCTION. In order to determine the effect of IR
n endothelial function, FMD was assessed before ischemia
nd at 20 min after reperfusion (n  13) (Fig. 1A).
imilarly, the effect of IR on smooth muscle function was
etermined in separate studies, by assessing the dilation of
he brachial artery in response to sublingual GTN (25 g)
efore and after IR (n 7) (Fig. 1B). Pilot studies indicated
hat GTN had a direct action to reduce IR injury if
dministered immediately before, but not when adminis-
ered 24 h before, IR. Therefore, to assess whether IR
ltered the dilator response to GTN, the control dilation to
TN was measured 24 h before IR and compared with the
ilation to GTN immediately after IR.
igure 1. Protocol of studies to determine the time course of remote
schemic preconditioning (RIPC). Flow-mediated dilation (FMD) of the
rachial artery was assessed before 20 min of arm ischemia (I) and at 20
in of reperfusion (R) (a). The effect of IR on brachial artery smooth
uscle function was determined by measuring dilation in response to
ublingual glyceryl trinitrate (GTN) (25 g) administered before and after
R (b). Because pilot studies had shown that GTN prevented endothelial
R injury when administered immediately but not 24 h before, the control
ilator response to GTN was determined 24 h before IR. The effect of
IPC of the contralateral arm on endothelial IR injury was determined by
pplying the RIPC stimulus immediately before IR (c). To determine the
ime course of protection by RIPC, the RIPC stimulus was applied 4 h (d),
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low-mediated dilation was assessed before and after IR
receded by RIPC (n  13) (Fig. 1C). In control studies
rachial FMD was measured before and after RIPC alone to
etermine whether RIPC had a direct effect on endothelial
unction (n  7).
IME COURSE OF THE PROTECTIVE EFFECT OF RIPC. Re-
ote IPC was applied 4 h (n 10) (Fig. 1D), 24 h (n 12)
Fig. 1E), and 48 h (n  8) (Fig. 1F) before IR; FMD was
easured before and after IR.
ECHANISM OF SPREAD OF THE RIPC STIMULUS: ROLE OF
HE AUTONOMIC NERVOUS SYSTEM. A venous cannula was
laced in a forearm vein in the left arm under local
nesthesia (1% lignocaine), and the NN-cholinergic antag-
nist trimetaphan camsylate (Cambridge Laboratories,
allsend, United Kingdom) was infused at 1 to 6 mg/min,
ith 1-mg/min dose increments at 5-min intervals. The
ose was increased until the heart rate response to a Valsalva
aneuver was abolished.
Eight volunteers underwent repeat assessment of the
ffects of IR alone (Fig. 1A), IR preceded by RIPC
mmediately (Fig. 1C), or 24 h before (Fig. 1E) on
ndothelial function. To determine the effect of autonomic
lockade on RIPC, the same volunteers received tri-
etaphan by infusion during the application of the RIPC
timulus immediately before IR (Fig. 2A) or 24 h before IR
n  7) (Fig. 2B). The effect of trimetaphan on baseline
MD (n  4) (Fig. 2C) and the endothelial response to IR
n  4) (Fig. 2D) was determined to exclude any direct
ffects on these measurements.
igure 2. Protocol of studies to determine the effect of autonomic blockade
n remote ischemic preconditioning (RIPC). Trimetaphan (1 to 6 mg/
in) was administered by continuous intravenous infusion to cause
utonomic nervous system blockade. To determine the effect of tri-
etaphan on early and late protection by RIPC, trimetaphan was infused
uring the RIPC stimulus that was applied immediately (a) and 24 h before
schemia and reperfusion (IR) (b). Protocols (c) and (d) were designed inn
rder to determine whether trimetaphan had direct effects on flow-
ediated dilation (FMD) or the endothelial response to IR, respectively.alculations and statistics. All data are expressed as
ean  SE unless otherwise stated. Brachial artery diam-
ter was measured in millimeters and dilation expressed as
ercentage increase from baseline diameter. Data were
ompared using the Student paired t test or repeated
easures analysis of variance (ANOVA), as appropriate.
or multiple comparisons (five groups), p values by
NOVA were Bonferroni-adjusted. In all cases, p  0.05
as considered statistically significant.
ESULTS
ll subjects tolerated the procedures without any complica-
ions. There were no differences in the responses between
en and women. The IR protocol had no effect on blood
ressure, heart rate, or basal flow at 20 min of reperfusion
data not shown). Mean brachial artery diameter was 3.9 
.1 mm.
ffect of IR on vascular dilator function. Ischemia-
eperfusion reduced brachial artery FMD (8.7  1.1%
efore IR vs. 4.9  1.2% after IR, p  0.001; n  13) (Fig.
A) but had no effect on blood flow during reactive
yperemia (peak to baseline volume flow ratio 8.8  0.9
efore IR vs. 11.2  1.3 after IR, p  NS). Ischemia
eperfusion had no effect on GTN dilation (9.3  2.0%
efore IR vs. 10.0  2.0%, p  NS; n  7) (Fig. 3B).
ffect of RIPC on endothelial function. Remote IPC did
igure 3. Effect of ischemia and reperfusion (IR) on endothelial and
mooth muscle function. Flow-mediated dilation (FMD) was 8.7  1.1%
t baseline (BL) and was reduced by IR (a) (IR 4.9  1.2%; *p  0.001 vs.
L, analysis of variance; n  13). Glyceryl trinitrate (GTN) dilation was
.3 2.0% at BL, and was unaffected by IR (b) (IR 10.0 2.0%; p NS,
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7.6  0.8% before RIPC vs. 7.2  0.9% after RIPC, p 
S; n  7). Remote IPC immediately before IR prevented
ndothelial dysfunction (FMD 9.4  0.7% before IR vs.
.0  0.8% after IR, p  NS; n  13) Fig. 4A).
ime-course of protection by RIPC. Remote IPC did
ot prevent endothelial dysfunction when applied 4 h before
R (FMD 8.6  1.1% before IR vs. 4.9  1.1% after IR,
 0.001; n 10) (Fig. 4B). When RIPC was applied 24 h
efore IR, FMD was preserved (FMD 8.7  1.1% before
R vs. 8.4  1.2% after IR, p  NS; n  12) (Fig. 4C).
imilar findings were observed when RIPC was applied
8 h before IR (FMD 10.0 0.9% before IR vs. 8.8 1.4%
fter IR, p  NS; n  8) (Fig. 4D).
ffect of autonomic blockade on RIPC. Autonomic
lockade by trimetaphan (5.5  1.3 mg/min) reduced
ystolic blood pressure (117.3  1.9 mm Hg at baseline vs.
00.8  2.1 mm Hg after autonomic blockade, p 
.0001), increased heart rate (65  2 beats/min at baseline
s. 89  2 beats/min after autonomic blockade, p 
.0001), but had no effect on diastolic blood pressure
65.4  2.0 mm Hg at baseline vs. 63.9  1.9 mm Hg after
utonomic blockade, p  NS). The increase in heart rate in
esponse to the Valsalva maneuver was prevented by tri-
etaphan (18.6  1.5 beats/min increase in heart rate at
aseline vs. 2.2  0.8 beats/min increase in heart rate after
utonomic blockade, p  0.0001). The hemodynamic
ffects of trimetaphan were only present while it was being
igure 4. Time course of the protective effect of remote ischemic precond
low-mediated dilation (FMD) was 9.4  0.7% at baseline (BL) and was
 NS vs. BL, analysis of variance [ANOVA]; n  13). Ischemia-reperfu
s. IRRIPC4 4.9  1.1%; *p  0.001, ANOVA; n  10). However, the
R (c) (BL 8.7  1.1% vs. IRRIPC24 8.4  1.2%; p  NS, ANOVA; n  1
 NS, ANOVA; n  8).nfused during RIPC; after cessation of the infusion, blood
ressure (114.7  2.4 mm Hg, p  NS vs. baseline) and
eart rate (62  2 beats/min, p  NS vs. baseline) had
eturned to normal by the time FMD was repeated.
Trimetaphan did not directly affect baseline brachial
rtery FMD (6.7 1.3% before trimetaphan vs. 6.8 0.9%
fter trimetaphan, p  NS; n  4); IR reduced FMD
7.3  1.2% before IR vs. 2.6  0.7% after IR, p  0.01;
 8) (Fig. 5A), and this was not significantly affected by
rimetaphan (FMD 8.5  1.2% before IR vs. 4.5  0.7%
fter IR, p  0.01; n  4). Remote IPC prevented
ndothelial dysfunction when applied immediately before
R (FMD 8.2  0.9% before IR vs. 7.0  0.8% after IR,
 NS; n  8) (Fig. 5B), but protection was diminished
hen RIPC was applied in the presence of systemic tri-
etaphan (FMD 8.3 1.1% before IR vs. 4.2 0.9% after
R, p  0.05; n  7) (Fig. 5C). Similarly, RIPC, applied
4 h before IR, prevented IR injury (FMD 8.0  1.2%
efore IR vs. 7.9  1.6% after IR, p  NS; n  7) (Fig.
D), but trimetaphan blocked the protective effect of RIPC
t this time point (FMD 7.3  1.0% before IR vs. 2.3 
.6% after IR, p  0.001; n  7) (Fig. 5E).
ISCUSSION
his study demonstrates for the first time in humans in vivo
hat RIPC prevents endothelial IR injury in conduit vessels
ith two temporally distinct phases of protection. An early
g (RIPC) on ischemia-reperfusion (IR)-induced endothelial dysfunction.
ected by IR preceded immediately by RIPC (a) (IRRIPC 8.0  0.8%;
educed FMD when RIPC was applied 4 h before IR (b) (BL 8.6  1.1%
of IR to reduce FMD was prevented when RIPC was applied 24 h beforeitionin
unaff
sion r
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Remote Ischemic Preconditioning in Humans August 2, 2005:450–6hase is activated immediately and disappears within 4 h; a
econd phase presents 24 h after the application of the
IPC stimulus and is sustained for at least 48 h. Both
hases of RIPC are dependent on intact autonomic func-
ion. If such protection extends beyond the vasculature, then
hese data suggest ways in which preconditioning can be
licited in patients undergoing planned procedures compli-
ated by IR injury.
ystemic protective effects of IPC. Ischemic precondi-
ioning, elicited by brief ischemic episodes, reduces tissue
amage occurring during prolonged ischemia (1), but the
erception that it was necessary to induce IPC in the at-risk
rgan has limited exploitation of this phenomenon in
linical practice. The realization that preconditioning has
ystemic effects to induce protection in tissues remote from
hose undergoing preconditioning substantially increases
he clinical applicability of preconditioning strategies (12).
igure 5. Effect of autonomic blockade on remote ischemic preconditionin
as reduced by ischemia reperfusion (IR) (a) (IR 2.6  0.7%; †p  0.01
revented by RIPC immediately before (b) (BL 8.2  0.9% vs. IRRIPC
s. IRRIPC24 7.9  1.2%; p  NS, ANOVA; n  7). Protection by
ntravenously) during RIPC immediately before IR (d) (BL 8.3  1.1% vs
R (e) (BL 7.3  1.0% vs. IRRIPC24 TRIM 2.3  0.6%; *p  0.001,n previous work we demonstrated that RIPC could be elicited by ischemia of nonvital tissues; limb ischemia in an
nimal model reduced experimental myocardial infarct size
nd in humans prevented IR injury to the endothelium of
he forearm resistance vasculature (25). Taken together
hese findings suggest that it may be possible to harness
ndogenous cardioprotection, triggered by ischemia of easily
ccessible tissues.
IPC of the limb protects against endothelial IR injury.
he present study demonstrates that RIPC prevents IR-
nduced endothelial dysfunction in conduit arteries, and is
onsistent with our previous data in the resistance vascula-
ure (25). The vascular endothelium is implicated in the
athogenesis of IR injury; reduced endothelial dilator and
nticoagulant function during IR injury may exacerbate
asospasm and encourage persistence of cellular aggregates
nd thrombus within conduit and resistance vessels. These
spects of endothelial dysfunction may directly affect the
C). Flow-mediated dilation (FMD) was 7.3  1.2% at baseline (BL) and
, analysis of variance [ANOVA]; n  8). The effect of IR on FMD was
0.8%; p  NS, ANOVA; n  8) or 24 h before IR (c) (BL 8.0  1.2%
was blocked by administration of trimetaphan (TRIM) (1 to 6 mg/min
RIPC TRIM 4.2  0.9%; ‡p  0.05, ANOVA; n  7) and 24 h before
VA; n  7).g (RIP
vs. BL
7.0 
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August 2, 2005:450–6 Remote Ischemic Preconditioning in Humansf preconditioning might be a consequence of preservation
f dilator function (30), although not all studies have shown
his (31,32). Changes in FMD were not explained by effects
f IR injury or RIPC on blood flow increases during reactive
yperemia. Moreover, the protective effect of RIPC was not
xplained by changes in smooth muscle responsiveness, as
IPC did not alter the GTN-induced dilation.
ime course of protection by RIPC. Animal studies
ndicate that RIPC offers protection from IR injury that
asts for up to 24 h (24,33,34). However, it has not been
stablished whether there are early and late phases of
rotection (as for IPC) rather than a single period of
rolonged protection. Our data confirm that RIPC mirrors
PC with an early phase of protection lasting only a few
ours after the RIPC stimulus, and followed 24 h later by a
econd window lasting for up to 48 h. The reappearance of
rotection and its prolonged time course is consistent with
ltered protein expression in the vessel wall, and it is
ossible that such changes may be similar to those identified
n second window IPC. Further studies are needed to
dentify these molecular mechanisms.
ffect of autonomic blockade on RIPC. One the most
ntriguing questions regarding RIPC is how the transfer of
he protective signal from the site of preconditioning to
emote tissues occurs. There is evidence for humoral medi-
tors that may include endogenous opioids (35,36). In
ddition, a neurogenic pathway has also been suggested,
ith evidence for involvement of the autonomic nervous
ystem in the mechanism of the early phase (14,16–18), and
ensory C fibers in the late phase (34,37,38). The present
tudy clearly implicates the autonomic nervous system in the
pread of protection during RIPC. The autonomic ganglion
locker trimetaphan was administered by intravenous infu-
ion at a dose sufficient to cause autonomic block (confirmed
y its effects on blood pressure, heart rate, and the Valsalva
esponse). Because of its short-lived action, autonomic
lockade was restricted to the RIPC phase of the protocols,
nd baseline hemodynamics were restored in advance of the
epeat assessment of FMD. Time-control studies confirmed
hat trimetaphan had no direct effect on FMD, or the
ndothelial response to IR injury. However, when admin-
stered during RIPC, it blocked its early and late protective
ffects on endothelial IR injury. It is possible that release of
ocal triggers of IPC (including bradykinin and adenosine)
ctivate the autonomic nervous system either directly
17,18) or via sensory nerves (34,37,38), and transfers the
ignal to the myocardium or other remote tissues. How this
eads to tissue protection is not clear at present, but animal
ata implicate a similar mechanism to that described for
lassical IPC, with activation of protein kinase C (14,22,23)
nd mitochondrial KATP channels (15,23,36,39). Our data
o not indicate which component of autonomic function
muscarinic or adrenergic) is involved, and further studies
re required to dissect these pathways.
tudy limitations. In our model, IR-induced endothelialnjury resolves spontaneously within 60 min of reperfusion26), consistent with “endothelial stunning” rather than
ecrosis in response to 20 min of ischemia. This may
xplain the complete abrogation of endothelial dysfunction
aused by RIPC that we observed. However, it also raises
oncerns that the protocol of limb RIPC that we used might
e insufficient to protect from more substantial injury, as
ould occur in the clinical setting. We have shown in a
revious study that a similar protocol of limb ischemia
educes infarct size in the pig after 40 min of coronary artery
cclusion (25). Moreover, recent preliminary data in hu-
ans indicates that preconditioning using limb ischemia
educes troponin T release from the myocardium after
ardiopulmonary bypass in children (40). These observa-
ions suggest that the limb is a suitable substrate to trigger
ystemic preconditioning, and that the present model of IR
njury is suitable to examine the time course of protection.
One additional potential limitation is the lack of speci-
city of trimetaphan, which also has alpha-adrenoreceptor
locking properties and induces the release of histamine.
oreover, trimetaphan has direct vasodilator actions, al-
hough the mechanisms of this effect are not currently
nown. Although these additional actions are unlikely to
ccount for the effects described in our study, unknown
ffects of the drug that alter the response of the vascular
ndothelium to RIPC cannot be excluded. One way of
liminating this potential source of error is to test whether
IPC can be induced in patients with autonomic nervous
ystem dysfunction.
onclusions. Irrespective of uncertainties regarding the
etails of mechanisms of IPC and RIPC, it is their
imilarity that is most striking, and strongly suggests that
PC and RIPC are two aspects of the same biological
echanism. When animal and human data are taken in
heir totality, this method of initiating IPC of vital tissues
ffers similar protection to that caused by direct IPC. The
resent study confirms that in humans RIPC offers endur-
ng (up to 48 h) protection against endothelial IR injury. If
his is applicable to other tissues, then our data suggest a
imple way in which the effect of RIPC to reduce ischemic
amage in clinical IR syndromes can be tested. Precondi-
ioning could be triggered 24 h in advance of cardiopulmo-
ary bypass surgery, angioplasty, or transplantation and
rovide up to 48 h of resistance to cardiac and noncardiac
schemia. Such investigations are likely to yield definitive
nformation on the clinical utility of RIPC.
eprint requests and correspondence: Mr. Stavros P. Loukogeor-
akis, Vascular Physiology Unit, Institute of Child Health, University
ollege London, 34 Great Ormond Street, London, WC1N 3JE,
nited Kingdom. E-mail: s.loukogeorgakis@ich.ucl.ac.uk.
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